Most NETs go undetected on standard imaging. Dr. Siegel explains how somatostatin receptor biology gives clinicians a molecular target for diagnosis.
United Theranostics Blog
Clinical Insights
Perspectives from United Theranostics on radiopharmaceutical therapy, molecular imaging, clinical research, and practical access to advanced cancer care.
Browse Topics
The Role of Somatostatin Receptors in Neuroendocrine Tumor Diagnosis
Most NETs go undetected on standard imaging. Dr. Siegel explains how somatostatin receptor biology gives clinicians a molecular target for diagnosis.
PLUVICTO® Before Chemotherapy: A New Option for Advanced Prostate Cancer
Dr. Munir Ghesani explains how PLUVICTO® can now be used before chemotherapy for some PSMA-positive prostate cancer patients. Here's what changed and who qualifies.
Understanding PSMA: What Patients Facing Prostate Cancer Should Know
PSMA is the molecular target behind today's most precise prostate cancer therapies. Nuclear Oncologist Dr. Babak Saboury explains what it is, how it works, and what your PSMA PET results…
Outsmarting Cancer: How AI and Digital Twins are Pioneering Precision Theranostics
United Theranostics Nuclear Oncologist Dr. Eliot Siegel explains how AI, digital twins and computational oncology are personalizing radiopharmaceutical therapy.
United Theranostics Is Redefining Cancer Treatment Through Precision Radiopharmaceutical Therapy
United Theranostics founding physician Dr. Michael Morris discusses how precision radiopharmaceutical therapy, personalized dosimetry, and expanding community-based care are shaping the future of cancer treatment.